Abramson Family Cancer Research Institute, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Cell and Developmental Biology, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
Abramson Family Cancer Research Institute, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Cell and Developmental Biology, 456 BRB II/III, 421 Curie Boulevard, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6160, USA.
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):23-31. doi: 10.1016/j.bbcan.2018.06.003. Epub 2018 Jun 28.
Clear cell renal cell carcinoma (ccRCC) is a malignancy characterized by deregulated hypoxia-inducible factor signaling, mutation of several key chromatin modifying enzymes, and numerous alterations in cellular metabolism. Pre-clinical studies have historically been limited to cell culture models, however, the identification of critical tumor suppressors and oncogenes from large-scale patient sequencing data has led to several new genetically engineered mouse models with phenotypes reminiscent of ccRCC. In this review, we summarize recent literature on these topics and discuss how they inform targeted therapeutic approaches for the treatment of ccRCC.
透明细胞肾细胞癌(ccRCC)是一种恶性肿瘤,其特征为缺氧诱导因子信号失调、几个关键染色质修饰酶的突变以及细胞代谢的许多改变。临床前研究历来限于细胞培养模型,然而,从大规模患者测序数据中鉴定关键的肿瘤抑制因子和癌基因,导致了几种具有类似于 ccRCC 表型的新型基因工程小鼠模型。在这篇综述中,我们总结了这些主题的最新文献,并讨论了它们如何为 ccRCC 的治疗提供靶向治疗方法。